Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7216 to 7230 of 8314 results

  1. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  2. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development Reference number: GID-HST10020 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  4. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  5. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued

  6. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

    Safe staffing guideline
    Discontinued

  7. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

    Safe staffing guideline
    Discontinued

  8. Management and organisational approaches to safe staffing

    Discontinued Reference number: GID-SGWAVE0761

    Safe staffing guideline
    Discontinued

  9. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

    Safe staffing guideline
    Discontinued

  10. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Technology appraisal guidance
    Published
    12 July 2023

  11. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  12. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  13. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Quality standard
    Last updated
    18 August 2016

  14. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

    Quality standard
    Published
    30 March 2011

  15. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Published
    2 July 2015